2022
The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study
Levitsky LL, Drews KL, Haymond M, Glubitosi-Klug RA, Katz L, Mititelu M, Tamborlane W, Tryggestad JB, Weinstock RS, Group T. The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study. Journal Of Diabetes And Its Complications 2022, 36: 108259. PMID: 36150365, DOI: 10.1016/j.jdiacomp.2022.108259.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBiomarkersCholesterol, LDLDiabetes Mellitus, Type 2Diabetic RetinopathyHumansObesityConceptsNon-proliferative diabetic retinopathyType 2 diabetesHigh-sensitivity C-reactive proteinObesity paradoxInflammatory biomarkersHDL cholesterolLDL cholesterolInsulin-like growth factor binding protein 1Sensitivity C-reactive proteinGrowth factor binding protein 1Today StudyPresence of retinopathyRelationship of obesityC-reactive proteinPlasminogen activator inhibitor-1Tumor necrosis factor receptor 1Digital fundus photographsNecrosis factor receptor 1Activator inhibitor-1Factor receptor 1Higher BMIObese participantsRisk markersDiabetic retinopathyInterleukin-6
2020
Refractive Error and Retinopathy Outcomes in Type 1 Diabetes The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Hainsworth DP, Gao X, Bebu I, Das A, de Koo L, Barkmeier AJ, Tamborlane W, Lachin JM, Aiello LP, Group D. Refractive Error and Retinopathy Outcomes in Type 1 Diabetes The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Ophthalmology 2020, 128: 554-560. PMID: 32941962, PMCID: PMC7956062, DOI: 10.1016/j.ophtha.2020.09.014.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaDiabetic retinopathyRefractive errorProliferative DRMacular edemaDiabetes controlDiabetes InterventionsRisk factorsUnadjusted modelsComplications Trial/EpidemiologyStages of DRCox proportional hazards modelDCCT treatment groupEDIC years 4Refractive error statusStandard fundus photographsAlbumin excretion rateDuration of diabetesIndependent risk factorDCCT/EDICDiastolic blood pressureSignificant macular edemaProliferative diabetic retinopathyPotential risk factorsProportional hazards model
2019
Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?
Gubitosi‐Klug R, Bebu I, White NH, Malone J, Miller R, Lorenzi GM, Hainsworth DP, Trapani VR, Lachin JM, Tamborlane WV, Group* F. Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? Pediatric Diabetes 2019, 20: 743-749. PMID: 31206973, PMCID: PMC7217664, DOI: 10.1111/pedi.12877.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesDiabetic retinopathyEye examEarly Treatment Diabetic Retinopathy Study (ETDRS) scaleMild non-proliferative diabetic retinopathyDiabetic Retinopathy Study scaleNon-proliferative diabetic retinopathyDiabetic retinopathy assessmentDiabetic retinopathy statusBaseline glycated hemoglobinClinical trial evidenceSignificant macular edemaProliferative diabetic retinopathyStandardized clinical trialsDiabetic retinopathy examinationsRetinopathy assessmentRetinopathy statusBaseline characteristicsComplications TrialMacular edemaCase seriesDiabetes controlIncident casesTrial evidence
2010
Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents
White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD, . Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents. Diabetes 2010, 59: 1244-1253. PMID: 20150283, PMCID: PMC2857905, DOI: 10.2337/db09-1216.Peer-Reviewed Original ResearchConceptsEDIC year 10Beneficial effectsPrior glycemic controlPrior intensive therapyProgression of retinopathyDCCT/EDICYear 10Type 1 diabetesComplications StudyDCCT closeoutMean A1CComplications TrialA1c levelsGlycemic controlIntensive therapySevere hypoglycemiaDiabetes controlINT groupDiabetes InterventionsDiabetic retinopathyCON groupSlow progressionConventional groupFormer adolescentsComparison of adult
2007
Clinical Outcomes and Cost-Effectiveness of Retinopathy Screening in Youth With Type 1 Diabetes
Huo B, Steffen AT, Swan K, Sikes K, Weinzimer SA, Tamborlane WV. Clinical Outcomes and Cost-Effectiveness of Retinopathy Screening in Youth With Type 1 Diabetes. Diabetes Care 2007, 30: 362-363. PMID: 17259509, DOI: 10.2337/dc06-1824.Peer-Reviewed Original Research
2006
Fulfilling the promise of insulin pump therapy in childhood diabetes
Tamborlane WV. Fulfilling the promise of insulin pump therapy in childhood diabetes. Pediatric Diabetes 2006, 7: 4-10. PMID: 16774611, DOI: 10.1111/j.1399-543x.2006.00171.x.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoring systemContinuous subcutaneous insulin infusion (CSII) treatmentType 1 diabetes mellitusRapid-acting insulin analoguesTreatment of T1DMComplications TrialDiabetes mellitusDiabetes controlGlucose monitoring systemChildhood diabetesFavorable outcomeInsulin analoguesInfusion treatmentInsulin pumpTherapyMinimal riskT1DMDiabetesInsulinTreatmentMellitusHypoglycemiaCSIIRecent introduction
1982
Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy.
Tamborlane WV, Puklin JE, Bergman M, Verdonk C, Rudolf MC, Felig P, Genel M, Sherwin R. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982, 5 Suppl 1: 58-64. PMID: 7188047.Peer-Reviewed Original ResearchConceptsPump treatmentProliferative retinopathyMetabolic controlInsulin pumpType I diabetic patientsFirst monthInsulin pump treatmentRetinal fluorescein leakageDiabetic microvascular complicationsTotal daily doseNormal glucose metabolismLong-term improvementBackground retinopathyMicrovascular complicationsCreatinine clearanceDiabetic nephropathyRenal functionSerum creatinineDaily doseDiabetic patientsDiabetic microangiopathyHemoglobin levelsPump therapyPlasma glucoseClinical endpoints